RSS

Sanfilippo syndrome type B (or MPS-IIIB)

Orchard Therapeutics, a clinical-stage biotechnology company, has acquired an exclusive licence to develop lentivirus-based autologous ex-vivo gene therapy for Sanfilippo syndrome type B (or MPS-IIIB) from The University of Manchester. more

News